Syndicated News

This blog is still in BETA

We are aware of any formatting errors. These stories are automatically pulled from RSS feeds. Due to the automated nature of the post, some images may appear small, and some links may not be clickable until our staff has had the opportunity to manicure the postings. Thank you for understanding.

December 01, 2014

Baxter submits BLA for extended half-life hemophilia treatment (BAX) - Seeking Alpha

December 01, 2014/ Michael

http://bit.ly/1rMtH9b Click to read full article...

Baxter submits BLA for extended half-life hemophilia treatment (BAX)Seeking AlphaBaxter International (BAX -0.4%) submits a biologics license application (BLA) to the FDA for BAX 855, an investigational extended half-life recombinant factor VIII treatment for hemophilia A based on Advate [Antihemophilic Factor (Recombinant)].Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half ...CNNMoneyBaxter Submits BLA For BAX 855Nasdaqall 4 news articles »

from Hemophilia - Google News http://bit.ly/1rMtH9b via IFTTT

Committee of Ten Thousand

ADVOCATES FOR PERSONS WITH HIV/AIDS, HEMOPHILIA, HCV, AND SICKLE CELL

MONITORING THE BLOOD SUPPLY AND PROTECTING PATIENT RIGHTS SINCE 1989

The Committee of Ten Thousand is a grass-roots, peer-led, education, advocacy and support organization. The majority of our constituency is persons with hemophilia who contracted HIV/AIDS from tainted blood products. We work in solidarity with all communities affected by the HIV/AIDS pandemic. COTT advocates for disenfranchised chronic disease communities, especially those communities dependent on a safe national blood supply. We are dedicated to the belief that persons with HIV/AIDS and all chronic diseases can lead productive and healthy lives.

Syndicated News

Syndicated News Feed

Baxter submits BLA for extended half-life hemophilia treatment (BAX) - Seeking Alpha

Committee of Ten Thousand

Quick Links - Sections